Search Weight Loss Topics:

Home » Testosterone » MetP Pharma Awarded US Patent for Potential Remyelination Therapy – Multiple Sclerosis News Today

MetP Pharmas patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO).

The patent, titled Treatment of Demyelinating Diseases (U.S. Appl. No. 16/506,830), is valid until 2039, andcovers the use of a steroid hormone, such as testosterone, in combination with a Hedgehog pathway modulator.

Steroid hormonesare a class of hormones defined by a particular molecular structure, and they play a variety of important roles throughout the body. Testosterone, in particular, is best known for its role in male sex development, but it also plays roles in the regular functioning of the brain, and has beenproposedas a therapeutic target for demyelinating diseases (those characterized by the loss of myelin, the protective coat of neurons). MS is a demyelinating disease.

The hedgehog pathway (named for the way flies with mutations in these genes look) is a molecular pathway through which cells transmit information to each other. It is best known for its importance in the development of numerous organ systems, including the brain, and also has been implicated to play a role in protecting neurons from demyelination.

Research suggesting that treatment with testosterone, together with a compound that modulates (changes the activity of) the hedgehog pathway, can drive remyelination and promote neural repair is the basis of the new patent.

The patent broadly covers the use of this therapeutic approach in demyelinating and inflammatory diseases of the nervous system, including MS, amyotrophic lateral sclerosis (ALS),Devics disease, Alzheimers disease, Guillain-Barr syndrome, and chronic inflammatory demyelinating polyneuropathy.

The patent covers any route of administration, favoring nasal spray. It also allows the administration of the two components together, one at a time, or some variation thereof.

According to MetP Pharma, this new therapeutic approach offers a new regenerative strategy with the potential of repairing already damaged myelin, whereas current therapeutic strategies lack an efficient regenerative potential.

Most medications used to treat MS are generally ineffective in progressive forms that are characterized by a chronic demyelination of axons. This new method can tremendously boost the remyelination of abnormal axons, and therefore may help to treat demyelinating diseases with high-unmet need better such as MS and ALS. We are excited to add this highly relevant method to our portfolio of granted patents, Claudia Mattern, PhD, chief scientific officer at MetP Pharma, saidin apress release.

MetP Pharma noted it is pursuing otherpatent applications in all major markets worldwide.

Marisa holds an MS in Cellular and Molecular Pathology from theUniversity of Pittsburgh, where she studied novel genetic drivers ofovarian cancer. She specializes in cancer biology, immunology, andgenetics. Marisa began working with BioNews in 2018, and haswritten about science and health for SelfHacked and the GeneticsSociety of America. She also writes/composes musicals and coachesthe University of Pittsburgh fencing club.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Read this article:
MetP Pharma Awarded US Patent for Potential Remyelination Therapy - Multiple Sclerosis News Today

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)	30313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120
Select Your US State	Select Your StateAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyoming
Program Choice	Select Your ProgramInjectable HGHInjectable TestoteroneInjectable SermorelinInjectable Weight LossInjectable HCG DietInjectable Vitamins
Confirm over 30 years old	Yes
Confirm that you resident in USA	Yes
This is a Serious Inquiry	Yes
Message:

Home » Testosterone » MetP Pharma Awarded US Patent for Potential Remyelination Therapy – Multiple Sclerosis News Today